Primary tumor characteristics and next-generation sequencing mutations as biomarkers for melanoma immunotherapy response.

Autor: Loo K; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.; Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA., Gauvin G; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Soliman I; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Renzetti M; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.; Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA., Deng M; Department of Statistics, Fox Chase Cancer Center, Philadelphia, PA, USA., Ross E; Department of Statistics, Fox Chase Cancer Center, Philadelphia, PA, USA., Luo B; Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA., Wu H; Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA., Reddy S; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Olszanski AJ; Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Farma JM; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Jazyk: angličtina
Zdroj: Pigment cell & melanoma research [Pigment Cell Melanoma Res] 2020 Nov; Vol. 33 (6), pp. 878-888. Date of Electronic Publication: 2020 Jul 07.
DOI: 10.1111/pcmr.12909
Abstrakt: Introduction: Considerable advances in melanoma have been realized through immunotherapy. The principal aim was to determine whether primary tumor characteristics or next-generation sequencing (NGS) could serve as markers of immunotherapy response.
Methods and Results: The study cohort consisted of 67 patients who received immunotherapy for recurrent or metastatic melanoma and for whom primary tumor biopsies and pathology reports were available. A subset of 59 patient tumors were profiled using an NGS panel of 50 cancer-related genes. Objective response rate to immunotherapy was assessed using RECIST v1.1 criteria. Progression-free survival (PFS) and overall survival (OS) were used as endpoints. Lymphovascular invasion (LVI) strongly correlated with an increased proportion of immunotherapy responders (p = .002). PFS interval (p = .003) and OS (p = .036) were significantly higher in patients with LVI. NRAS mutation was more strongly correlated with an increased proportion of immunotherapy responders (p =.050). PFS was significantly higher in patients with NRAS mutation (p = .042); no difference in OS (p = .111).
Discussion: This analysis demonstrates an association between lymphovascular invasion and immunotherapy response. Additionally, NGS mutation analysis demonstrated a potential association between NRAS mutations and immunotherapy response.
(© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: